^
    5ms
    Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=15, Terminated, Kite, A Gilead Company | N=40 --> 15 | Trial completion date: Feb 2026 --> May 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2026 --> May 2024; Study was terminated due to futility
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • CAR T-Cell Therapy
    |
    cyclophosphamide • fludarabine IV • KITE-222
    7ms
    Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Kite, A Gilead Company | Recruiting --> Active, not recruiting | Trial completion date: Jan 2039 --> Feb 2026 | Trial primary completion date: Oct 2024 --> Feb 2026
    Enrollment closed • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    cyclophosphamide • fludarabine IV • KITE-222
    7ms
    Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells (clinicaltrials.gov)
    P2, N=700, Enrolling by invitation, Kite, A Gilead Company | Trial completion date: Mar 2041 --> Dec 2040 | Trial primary completion date: Mar 2041 --> Dec 2040
    Trial completion date • Trial primary completion date
    |
    Yescarta (axicabtagene ciloleucel) • Tecartus (brexucabtagene autoleucel) • KITE-222 • KITE-363 • KITE-439 • KITE-585 • KITE-718
    9ms
    Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=40, Recruiting, Kite, A Gilead Company | Trial primary completion date: Jan 2024 --> Oct 2024
    Trial primary completion date • CAR T-Cell Therapy
    |
    cyclophosphamide • fludarabine IV • KITE-222
    over1year
    Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells (clinicaltrials.gov)
    P2, N=700, Enrolling by invitation, Kite, A Gilead Company | Trial completion date: Nov 2026 --> Mar 2041 | Trial primary completion date: Nov 2026 --> Mar 2041
    Trial completion date • Trial primary completion date
    |
    Yescarta (axicabtagene ciloleucel) • Tecartus (brexucabtagene autoleucel) • KITE-222 • KITE-363 • KITE-439 • KITE-585 • KITE-718